Multicenter randomized controlled clinical study on resuscitate emergency shock patients with sodium potassium magnesium calcium and glucose injection

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001788

Enrollment

Unknown

Registered

2011-12-12

Start date

2011-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with septic or hypovolemic shock were included in the study

Interventions

A:lactated Ringer's solution

B:sodium potassium magnesium calcium and glucose injection

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. the subjects voluntarily agreed to participate in this study and signed written informed consent; 2. aged 18 to 70; 3. sex is unlimited; 4. all kinds of severe infection that meet up with diagnostic criteria of septic shock; 5. upper gastrointestinal hemorrhage that meet up with diagnostic criteria of hypovolemic shock.

Exclusion criteria

Exclusion criteria: 1. severe chronic cardiovascular, hepatic, respiratory, renal, hematologic or other organ system diseases, severe multiple or compound injuries, end-stage cancer, perioperative period (e.g. acute abdominal disease), patients after cardiopulmonary resuscitation,or patients who have poor prognosis that the fluid resuscitation doesn't work; 2. hypovolemic shock caused by trauma, cardiogenic shock, anaphylactic shock and neurogenic shock; 3. confirmed lower gastrointestinal hemorrhage or upper gastrointestinal hemorrhage caused by phlebeurysma; 4. diabetes, hypothyroidism or other metabolic disorders; 5. random blood glucose >=11.10mmol/L before the test; 6. hyperkalemia, serum potassium >=5.00mmol/L before the test; 7. DIC or coagulation defects caused by shock; 8. compliance is not good when is treated (e.g. use peripherally inserted central catheter) or can not finish the treatment; 9. drug or food allergies history, anaphylaxis or allergy to the drug components included in the study; 10. pregnancy or lactating women; 11. participated in other clinical trials within 3 months; 12. one who cannot be included in the study after being comprehensive considered by the clinician.

Design outcomes

Primary

Measure	Time frame
28-day Mortality;hemodynamic paramete;	—

Secondary

Measure	Time frame
pH volue;	—

Contacts

Public ContactZhouyaxiong

yuyan10@126.com+86 13980690668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026